GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,450 ($19.52) price objective by equities researchers at Bank of America in a research note issued to investors on Wednesday. The brokerage presently has a “neutral” rating on the stock. Bank of America’s target price suggests a potential upside of 13.46% from the company’s current price.
A number of other research analysts have also weighed in on GSK. Deutsche Bank set a GBX 1,610 ($21.67) target price on GlaxoSmithKline and gave the company a “neutral” rating in a report on Tuesday, August 8th. Goldman Sachs Group set a GBX 1,900 ($25.57) target price on GlaxoSmithKline and gave the company a “buy” rating in a report on Tuesday, August 8th. Berenberg Bank reduced their target price on GlaxoSmithKline from GBX 1,885 ($25.37) to GBX 1,835 ($24.70) and set a “buy” rating for the company in a report on Wednesday, August 9th. Jefferies Group cut their price objective on GlaxoSmithKline from GBX 1,900 ($25.57) to GBX 1,750 ($23.55) and set a “buy” rating for the company in a report on Thursday, August 24th. Finally, Liberum Capital reissued a “buy” rating and set a GBX 1,900 ($25.57) price objective on shares of GlaxoSmithKline in a report on Wednesday, August 30th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,577.14 ($21.23).
GlaxoSmithKline (LON GSK) opened at GBX 1,278 ($17.20) on Wednesday. GlaxoSmithKline has a twelve month low of GBX 1,277.50 ($17.19) and a twelve month high of GBX 1,724.50 ($23.21).
In other news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.55) per share, for a total transaction of £16,430.52 ($22,113.76). Also, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average price of GBX 1,518 ($20.43) per share, with a total value of £7,180.14 ($9,663.71). In the last 90 days, insiders have purchased 1,576 shares of company stock valued at $2,400,376.
ILLEGAL ACTIVITY WARNING: This piece was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/06/bank-of-america-analysts-give-glaxosmithkline-gsk-a-gbx-1450-price-target.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.